UK markets close in 2 hours 52 minutes
  • FTSE 100

    7,188.30
    -34.80 (-0.48%)
     
  • FTSE 250

    22,899.70
    -66.97 (-0.29%)
     
  • AIM

    1,238.11
    +0.02 (+0.00%)
     
  • GBP/EUR

    1.1857
    -0.0006 (-0.05%)
     
  • GBP/USD

    1.3808
    -0.0017 (-0.13%)
     
  • BTC-GBP

    47,089.63
    +341.44 (+0.73%)
     
  • CMC Crypto 200

    1,538.21
    +57.40 (+3.88%)
     
  • S&P 500

    4,536.19
    +16.56 (+0.37%)
     
  • DOW

    35,609.34
    +152.03 (+0.43%)
     
  • CRUDE OIL

    82.92
    -0.50 (-0.60%)
     
  • GOLD FUTURES

    1,783.20
    -1.70 (-0.10%)
     
  • NIKKEI 225

    28,708.58
    -546.97 (-1.87%)
     
  • HANG SENG

    26,017.53
    -118.49 (-0.45%)
     
  • DAX

    15,522.03
    -0.89 (-0.01%)
     
  • CAC 40

    6,680.83
    -24.78 (-0.37%)
     

New Medical Study Reports Reduced Depression and Anxiety Symptoms With Low Doses of CBD

·2-min read

Human Observational Study, Led by Realm of Caring Cannabis Research Group, Backs Findings from Published Animal Studies

COLORADO SPRINGS, Colo., September 21, 2021--(BUSINESS WIRE)--Realm of Caring (RoC), a nonprofit dedicated to cannabinoid research, has published its latest paper in the medical journal Frontiers in Psychiatry, examining the benefits of medicinal cannabis products for individuals with anxiety and depression. The longitudinal study, using data gathered from RoC’s Observational Research Registry (ORR), showed that individuals who initiated use of artisanal cannabidiol (CBD) products or continued use of CBD products at follow-up endorsed significant reductions in both anxiety and depression, improved sleep, and less pain compared with those not using CBD.

"The biggest misconception this study addresses is that CBD doses need to be between 400-600 mg before positive psychiatric effects can be achieved," said Dr. Nicolas Schlienz, Research Director for Realm of Caring. "We observed positive effects in people taking an average of only about 60 mg per day, 1/10th of that dose."

Schlienz conceptualized and co-authored the study alongside RoC’s President, Heather Jackson; Dr. Marcel Bonn-Miller, Vice President, Human and Animal Research at Canopy Growth Corporation; Dr. Ryan Vandrey, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine; Erin Martin, Predoctoral Fellow at the Medical University of South Carolina; and Dr. Justin Strickland, Instructor at Johns Hopkins University.

Researchers sourced data from an online web survey conducted over a four-year period (2016-2020) focusing on participants’ self-reported anxiety and depression symptoms, and the need for an assessment on non-pharmaceutical CBD products widely available to consumers. For information on joining RoC’s ongoing research, visit www.realmofcaring.org.

About Realm of Caring

Through research and education, Realm of Caring (RoC) is facilitating the mainstream acceptance of cannabinoid-based therapies and building an empowered community. RoC is committed to research into novel healthcare options to improve quality of life. The organization leverages a deep bench of experience and leads with compassion to provide trusted resources, create support and build community for all who seek it. The 501(c)(3) high-impact independent public charitable organization has served tens of thousands of families and healthcare professionals since its inception in 2013.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005369/en/

Contacts

Lindsey Clarke
Grasslands: A Journalism-Minded Agency
lindsey@mygrasslands.com
970.690.8150

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting